Aaron I. Davis, Director, 10% Owner at Odonate Therapeutics, Inc. (ODT), bought 200,000 shares at $20.94 ($4.5M) on 2018-03-22, disclosed to the SEC on 2018-03-26.
Open-market purchase of $4.5M ODT by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.94 | 23,407 | $490K | 10.8% |
| 2 | $20.94 | 23,407 | $490K | 10.8% |
| 3 | $23.96 | 42,943 | $1.0M | 22.6% |
| 4 | $23.96 | 42,943 | $1.0M | 22.6% |
| 5 | $22.41 | 33,650 | $754K | 16.6% |
| 6 | $22.41 | 33,650 |
| $754K |
| 16.6% |
| Total | $22.73 avg | 200,000 | $4.5M | 100% |
| Filing → |
| TYRA | SELL | 2023-02-13 | $4.4M | — | Filing → |
| RAIN | BUY | 2022-11-08 | $11.3M | — | Filing → |
| ITOS | SELL | 2022-05-11 | $20.2M | — | Filing → |